Back to today’s briefing

Story perspectives

FDA Approves First Gene-Edited Therapy for RDEB

5/6/2025

22 3

Summary

Story summary

The FDA has made a groundbreaking decision by approving ZEVASKYN, the first-ever gene-edited therapy for recessive dystrophic epidermolysis bullosa (RDEB). In the Phase 3 VIITAL study, a single treatment remarkably healed 81% of chronic wounds within six months. Set to launch in 2025, this innovative therapy promises to transform lives and lower healthcare expenses.

1 of 1

Story summary

The FDA has made a groundbreaking decision by approving ZEVASKYN, the first-ever gene-edited therapy for recessive dystrophic epidermolysis bullosa (RDEB). In the Phase 3 VIITAL study, a single treatment remarkably healed 81% of chronic wounds within six months. Set to launch in 2025, this innovative therapy promises to transform lives and lower healthcare expenses.